Teva Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Teva Pharma (TEVA) PT Lowered to $20 at RBC Capital
February 14, 2019 6:50 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Teva Pharma (NYSE: TEVA) to $20.00 (from $22.00) while maintaining a Sector Perform rating.
... MoreTeva Pharma (TEVA) Misses Q4 EPS by 1c, FY Guidance Misses
February 13, 2019 7:01 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.53, $0.01 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $4.6 billion versus the consensus estimate of $4.52 billion.
GUIDANCE:
Teva Pharma sees FY2019 EPS of $2.20-$2.50, versus the consensus... More
